Study of Single and Multiple Doses of PRS-220 Administered by Oral Inhalation in Healthy Subjects

Healthy Clinical Trial

Official title:

A Phase 1, Randomized, Blinded, Placebo Controlled, Single and Multiple Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of PRS 220 Administered by Oral Inhalation in Healthy Subjects.

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT05473533
• Other study ID #: PRS-220-PCS_11_21
• Status: Completed
• Phase: Phase 1
• Start date: October 31, 2022
• Est. completion date: August 11, 2023

Study information

• Verified date: November 2022
• Source: Pieris Australia Pty Ltd
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

A dose escalating study of PRS-220 administered by oral inhalation in healthy subjects

Description:

PRS-220 is a new drug being developed for treatment of idiopathic pulmonary fibrosis (IPF). The main purpose of this study is to investigate the safety, tolerability, pharmacokinetics, and immunogenicity of single and multiple ascending doses of PRS-220 in healthy subjects.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 64
• Est. completion date: August 11, 2023
• Est. primary completion date: August 11, 2023
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 64 Years

Eligibility

Inclusion Criteria:

1. The subject is able to provide written ICF prior to Screening.

2. The subject is healthy male or female (only if female satisfies criteria to be classified as a "woman of non-childbearing potential"), between the ages of 18 and 64 (inclusive) at Screening.

• Women of non-childbearing potential are defined as:

• Post-menopausal (12 consecutive months of spontaneous amenorrhea without an alternative medical cause); or is

• Surgically sterile (having undergone one of the following procedures:

hysterectomy, bilateral oophorectomy, or bilateral salpingectomy) and at least six weeks post-sterilization.

Males must be surgically sterile or abstinent or not engaged in sexual relations with a woman of childbearing potential (WOCBP) or, if engaged in sexual relations with a WOCBP, the subject must agree to consistently use an adequate method of contraception, which is defined as use of a condom by the male partner combined with use of a highly effective method of contraception by the female partner. A highly effective method of contraception is one that has a failure rate of < 1% when used consistently and correctly.

3. The subject has a body mass index (BMI) between18 and 32 kg/m2 (inclusive) at Screening.

4. The subject has a forced expiratory volume in one second (FEV1) =80% of the predicted value at Screening.

5. Percent predicted forced expiratory volume in one second (ppFEV1) measurements during Screening (any time between Day -28 and Day -2) and Check-in (Day -1) (at least 3 days apart; and, centrally confirmed) with absolute difference <10 percentage units, ppFEV1.

6. The subject agrees to comply with all protocol requirements.

Exclusion Criteria:

1. The subject has clinically significant (at the discretion of the investigator) abnormalities in physical examination, vital signs, hematology/chemistry/urinalysis, or ECG at Screening that would render a subject unsuitable for inclusion. Including but not limited to:

• Alanine aminotransferase (ALT) >1.5× upper limit of normal (ULN), aspartate aminotransferase (AST) >1.5× ULN, gamma-glutamyl transferase (GGT) >1.5× ULN, or alkaline phosphatase >1.5× ULN

• C-reactive protein (CRP) >2.9 mg/L

• After at least five minutes of supine rest, have a systolic blood pressure <90 or >140 mmHg or diastolic blood pressure <40 or >90 mmHg at Screening

2. The subject has any significant medical condition that may put the subject at risk if participating in this study, at the discretion of the investigator (resolved childhood asthma can be included).

3. The subject has a history of malignancy within the past five years, except for basal cell carcinoma, squamous cell carcinoma, and cervical cancer in situ.

4. The subject has upper respiratory tract infections within 14 days prior to the first dose of the study drug product (Day 1); or lower respiratory tract infection within three months prior to Screening (with regard to COVID 19, sites should adhere to local guidelines).

5. The subject has any clinically significant illness, medical/surgical procedure, or trauma within eight weeks prior to the first dose of the study drug product (Day 1).

6. The subject has any history of smoking (e.g., cigarettes, e-cigarettes/vaping, marijuana, cigars) within one month prior to Screening.

7. The subject has received treatment with another investigational drug product within the past 30 days (or five half-lives or the length of the drug's pharmacodynamic effect, whichever is longer) prior to the first dose of the study drug product (Day 1).

8. The subject has a history of severe allergic reaction to any component of PRS-220 including its excipients.

9. The subject has a history of alcohol and/or other substance abuse or addiction within 12 months prior to Screening, as determined by the investigator, or a positive test result for alcohol or drugs of abuse at Screening or prior to the first dose of the study drug product (Day 1).

10. The subject has taken any of the following medications:

• Prescription medication or herbal supplements within 14 days (or five half-lives, whichever is longer) prior to the first dose of the study drug product

• Non-prescription medication, vitamins (e.g., biotin), or minerals within seven days prior to the first dose of the study drug product

Note: Acetaminophen (paracetamol, <4 g per day), nonsteroidal anti-inflammatory drugs (NSAID) medication, or salicylic acid containing topical preparation may be used within one day prior to the first dose of the study drug product.

11. The subject is consuming excessive amounts of caffeine, defined as more than four servings of coffee, tea, cola, or other caffeinated beverages per day (one serving is approximately 120 mg of caffeine); or the subject refuses to abstain from caffeine-containing foods or caffeinated beverages (e.g., coffee, tea, cola, energy drinks) within three days prior to Day -1 and until discharge from the clinical research unit.

12. The subject has previously enrolled in this study.

13. The subject has a positive test result for hepatitis B surface antigen, hepatitis C virus antibody, or human immunodeficiency virus (HIV) types 1 or 2 antibodies at Screening.

14. The subject has donated blood or blood products >450 mL within 30 days before the first dose of study drug product. The subject has donated plasma >450 mL within seven days prior to the first dose of the study drug product.

Related Conditions & MeSH terms

• Healthy
• Respiratory Aspiration

Intervention

Drug:
• Placebo
Placebo; formulated as solution for inhalation without active substance.
• PRS-220
PRS-220; formulated as solution for inhalation.

Locations

Country	Name	City	State
Australia	Nucleus Network Pty Ltd.	Melbourne	Victoria

Sponsors (1)

Lead Sponsor	Collaborator
Pieris Australia Pty Ltd

Country where clinical trial is conducted

Australia, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Safety & tolerability - AEs	The safety and tolerability of PRS-220 will be assessed based on the frequency (no. per patient, cohort, and treatment [PRS-220 vs. placebo]) and severity (based on the Common Terminology Criteria for Adverse Events, CTCAE) of adverse events (AEs) throughout the study and until 28 days after the last dose.	29 days (SAD), 57 days (MAD)
Primary	Safety & tolerability - SAEs	The safety and tolerability of PRS-220 will be assessed based on the frequency (no. per patient, cohort, and treatment [PRS-220 vs. placebo]) and severity (based on the Common Terminology Criteria for Adverse Events, CTCAE) of serious adverse events (SAEs) throughout the study and until 28 days after the last dose.	29 days (SAD), 57 days (MAD)
Primary	Safety & tolerability - TEAEs	The safety and tolerability of PRS-220 will be assessed based on the frequency (no. per patient, cohort, and treatment [PRS-220 vs. placebo]) and severity (based on the Common Terminology Criteria for Adverse Events, CTCAE) of treatment-emergent adverse events (TEAEs) throughout the study and until 28 days after the last dose.	29 days (SAD), 57 days (MAD)
Primary	Safety & tolerability - Vital signs (change in blood pressure)	To assess changes in blood pressure (systolic and diastolic, mm Hg) as a criterion of safety and tolerability throughout the study.	29 days (SAD), 57 days (MAD)
Primary	Safety & tolerability - Vital signs (change in heart rate)	To assess changes in heart rate (beats per minute, BPM) as a criterion of safety and tolerability throughout the study.	29 days (SAD), 57 days (MAD)
Primary	Safety & tolerability - Vital signs (change in body temperature)	To assess changes in body temperature (degrees Celsius) as a criterion of safety and tolerability throughout the study.	29 days (SAD), 57 days (MAD)
Primary	Safety & tolerability - Vital signs (change in respiratory rate)	To assess changes in respiratory rate (breaths per minute) as a criterion of safety and tolerability throughout the study.	29 days (SAD), 57 days (MAD)
Primary	Safety & tolerability - Vital signs (change in oxygen saturation)	To assess changes in oxygen saturation (sO2, %) as a criterion of safety and tolerability throughout the study.	29 days (SAD), 57 days (MAD)
Primary	Safety & tolerability - 12-lead ECGs	To assess changes in cardiovascular system function (change in QTC parameters) as a criterion of safety and tolerability throughout the study.; 12-lead ECGs will be assessed by a central reader.	29 days (SAD), 57 days (MAD)
Primary	Safety & tolerability - Spirometry (FEV1)	To assess changes in FEV1 (forced expiratory volume in one second, L) as a criterion of safety and tolerability throughout the study.; Spirometry recordings will be assessed by a central reader.	29 days (SAD), 57 days (MAD)
Primary	Safety & tolerability - Spirometry (PEFR)	To assess changes in PEFR (peak expiratory flow rate, L/s) as a criterion of safety and tolerability throughout the study.; Spirometry recordings will be assessed by a central reader.	29 days (SAD), 57 days (MAD)
Primary	Safety & tolerability - Spirometry (FVC)	To assess changes in FVC (forced vital capacity, % predicted) as a criterion of safety and tolerability throughout the study.; Spirometry recordings will be assessed by a central reader.	29 days (SAD), 57 days (MAD)
Primary	Safety & tolerability - Serum chemistry (sodium)	To assess changes in sodium levels (mmol/L) throughout the study.	29 days (SAD), 57 days (MAD)
Primary	Safety & tolerability - Serum chemistry (potassium)	To assess changes in potassium levels (mmol/L) throughout the study.	29 days (SAD), 57 days (MAD)
Primary	Safety & tolerability - Serum chemistry (chloride)	To assess changes in chloride levels (mmol/L) throughout the study.	29 days (SAD), 57 days (MAD)
Primary	Safety & tolerability - Serum chemistry (calcium)	To assess changes in calcium levels (mmol/L) throughout the study.	29 days (SAD), 57 days (MAD)
Primary	Safety & tolerability - Serum chemistry (magnesium)	To assess changes in magnesium levels (mmol/L) throughout the study.	29 days (SAD), 57 days (MAD)
Primary	Safety & tolerability - Serum chemistry (bicarbonate)	To assess changes in bicarbonate levels (mmol/L) throughout the study.	29 days (SAD), 57 days (MAD)
Primary	Safety & tolerability - Serum chemistry (urea/urea nitrogen)	To assess changes in urea/urea nitrogen (BUN) levels (mmol/L) throughout the study.	29 days (SAD), 57 days (MAD)
Primary	Safety & tolerability - Serum chemistry (creatinine)	To assess changes in creatinine levels (µmol/L) throughout the study.	29 days (SAD), 57 days (MAD)
Primary	Safety & tolerability - Serum chemistry (albumin)	To assess changes in albumin levels (g/L) throughout the study.	29 days (SAD), 57 days (MAD)
Primary	Safety & tolerability - Serum chemistry (bilirubin)	To assess changes in bilirubin levels (µmol/L) throughout the study.	29 days (SAD), 57 days (MAD)
Primary	Safety & tolerability - Serum chemistry (uric acid)	To assess changes in uric acid levels (mmol/L) throughout the study.	29 days (SAD), 57 days (MAD)
Primary	Safety & tolerability - Serum chemistry (creatine kinase)	To assess changes in creatine kinase (CK) levels (U/L) throughout the study.	29 days (SAD), 57 days (MAD)
Primary	Safety & tolerability - Serum chemistry (lactate dehydrogenase)	To assess changes in lactate dehydrogenase (LDH) levels (U/L) throughout the study.	29 days (SAD), 57 days (MAD)
Primary	Safety & tolerability - Hematology (hematocrit)	To assess changes in hematocrit levels (%) throughout the study.	29 days (SAD), 57 days (MAD)
Primary	Safety & tolerability - Hematology (red blood cell count)	To assess changes in total red blood cell (RVC) counts (10^6/µL) throughout the study.	29 days (SAD), 57 days (MAD)
Primary	Safety & tolerability - Hematology (platelet count)	To assess changes in platelet counts (10^9/µL) throughout the study.	29 days (SAD), 57 days (MAD)
Primary	Safety & tolerability - Hematology (white blood cell count)	To assess changes in white blood cell (WBC) counts (10^3/µL) throughout the study.	29 days (SAD), 57 days (MAD)
Primary	Safety & tolerability - Hematology (neutrophil percentage)	To assess changes in neutrophil percentage (%) throughout the study.	29 days (SAD), 57 days (MAD)
Primary	Safety & tolerability - Hematology (lymphocyte percentage)	To assess changes in lymphocyte percentage (%) throughout the study.	29 days (SAD), 57 days (MAD)
Primary	Safety & tolerability - Hematology (eosinophil percentage)	To assess changes in eosinophil percentage (%) throughout the study.	29 days (SAD), 57 days (MAD)
Primary	Safety & tolerability - Hematology (basophil percentage)	To assess changes in basophil percentage (%) throughout the study.	29 days (SAD), 57 days (MAD)
Primary	Safety & tolerability - Hematology (monocyte percentage)	To assess changes in monocyte percentage (%) throughout the study.	29 days (SAD), 57 days (MAD)
Primary	Safety & tolerability - Urinalysis (turbidity)	To assess changes in turbidity of the urine sample as part of a standard urinalysis panel throughout the study.	29 days (SAD), 57 days (MAD)
Primary	Safety & tolerability - Urinalysis (specific gravity)	To assess changes in specific gravity of the urine sample as part of a standard urinalysis panel throughout the study.	29 days (SAD), 57 days (MAD)
Primary	Safety & tolerability - Urinalysis (pH)	To assess changes in pH of the urine sample as part of a standard urinalysis panel throughout the study.	29 days (SAD), 57 days (MAD)
Primary	Safety & tolerability - Urinalysis (protein)	To assess changes in protein levels of the urine sample as part of a standard urinalysis panel throughout the study.	29 days (SAD), 57 days (MAD)
Primary	Safety & tolerability - Urinalysis (glucose)	To assess changes in glucose levels (positive/negative) of the urine sample as part of a standard urinalysis panel throughout the study.	29 days (SAD), 57 days (MAD)
Primary	Safety & tolerability - Urinalysis (ketone)	To assess changes in ketone levels (positive/negative) of the urine sample as part of a standard urinalysis panel throughout the study.	29 days (SAD), 57 days (MAD)
Primary	Safety & tolerability - Urinalysis (blood)	To assess changes in blood levels (positive/negative) of the urine sample as part of a standard urinalysis panel throughout the study.	29 days (SAD), 57 days (MAD)
Primary	Safety & tolerability - Urinalysis (nitrite)	To assess changes in nitrite levels (positive/negative) of the urine sample as part of a standard urinalysis panel throughout the study.	29 days (SAD), 57 days (MAD)
Primary	Tolerability - Taste characteristics	Tolerability will be assessed by an open-ended questionnaire that assesses the taste characteristics of PRS-220.; Subjects must choose between values from 0 to 10; where "0" represents no/low agreement with the statement and "10" represents extreme/definite agreement with the statement.	Once after first dose on Day 1 (SAD, MAD) and again on Day 15 (MAD)
Secondary	Pharmacokinetics of PRS-220 - Serum concentrations (AUC0-t)	- Area under the serum concentration versus time curve (AUC) from time 0 to the last quantifiable concentration (AUC0-t)	29 days (SAD), 57 days (MAD)
Secondary	Pharmacokinetics of PRS-220 - Serum concentrations (AUC0-inf)	- AUC from time 0 extrapolated to infinity (Day 1) (AUC0-inf)	29 days (SAD), 57 days (MAD)
Secondary	Pharmacokinetics of PRS-220 - Serum concentrations (AUC0-tau)	- AUC from time 0 to the time of the dosing interval (tau; AUC0-tau); tau = 12 h	29 days (SAD), 57 days (MAD)
Secondary	Pharmacokinetics of PRS-220 - Serum concentrations (AR)	- Accumulation ratio (AR), calculated during the multiple ascending dose (MAD) portion as AUC0-tau (Day 29)/AUC0-tau (Day 1); tau = 12 h	29 days (SAD), 57 days (MAD)
Secondary	Pharmacokinetics of PRS-220 - Serum concentrations (Cmax)	- Maximum observed serum concentration (Cmax)	29 days (SAD), 57 days (MAD)
Secondary	Pharmacokinetics of PRS-220 - Serum concentrations (Tmax)	- Time to reach maximum observed serum concentration (Tmax)	29 days (SAD), 57 days (MAD)
Secondary	Pharmacokinetics of PRS-220 - Serum concentrations (Kel)	- Terminal elimination rate constant (Kel)	29 days (SAD), 57 days (MAD)
Secondary	Pharmacokinetics of PRS-220 - Serum concentrations (t1/2)	- Terminal elimination half-life (t1/2)	29 days (SAD), 57 days (MAD)
Secondary	Pharmacokinetics of PRS-220 - Serum concentrations (MRT)	- Mean residence time (MRT)	29 days (SAD), 57 days (MAD)
Secondary	Immunogenicity - Anti-drug antibodies (ADA)	Immunogenicity potential of PRS-220 will be assessed by the presence and titer of anti-drug antibodies (ADA) in the serum.	29 days (SAD), 57 days (MAD)